Veterinary dermatology最新文献

{"title":"Epidemiology of Canine Cutaneous Histiocytoma: Insights From Age and Topographic Clustering.","authors":"C De Moura, K Pinello, J Catarino, J Niza-Ribeiro, J Santos, P Faísca","doi":"10.1111/vde.70068","DOIUrl":"10.1111/vde.70068","url":null,"abstract":"<p><strong>Background: </strong>Canine cutaneous histiocytoma (CCH) is a benign Langerhans-cell tumour that often regresses spontaneously via inflammation.</p><p><strong>Objectives: </strong>To estimate incidence and characterise age and breed-anatomical-site patterns using two complementary clustering analyses.</p><p><strong>Materials and methods: </strong>A total of 359 histopathologically-confirmed CCHs from a private veterinary laboratory in Portugal (January 2020-January 2022) were analysed with dog-population denominators from the national registry (SIAC). Incidence rates (IR) were calculated for Lisbon-Setúbal; breed- and sex-specific relative risks (RR) were estimated. Age was modelled with BIC-selected Gaussian mixtures; breed-site patterns were summarised by hierarchical clustering of site frequencies (heatmaps).</p><p><strong>Results: </strong>Cases concentrated in young dogs (≤ 2 years, 48.8%) and males (58.5%). Age clustering defined three bands (≈ ≤ 1.5, 1.5-3.5, > 3.5 years) with differing breed and site distributions. Breed-site clustering revealed recurring anatomical predilections by breed and sex. The annual IR in Lisbon-Setúbal was 4.0 per 10,000 dogs (3.5 in females; 4.4 in males). Risk was highest in French bulldogs (RR 11.5; IR 34.1) and Boxers (RR 8.3; IR 24.5) versus mixed-breed dogs (p < 0.001).</p><p><strong>Conclusions and clinical relevance: </strong>Canine cutaneous histiocytoma (CCH) shows clear age bands and breed-linked anatomical predilections; these patterns help prioritise ages, sites and breeds for studies of inflammation-mediated regression.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"780-787"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147623363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study.","authors":"Kosuke Horita, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda","doi":"10.1111/vde.70062","DOIUrl":"10.1111/vde.70062","url":null,"abstract":"<p><strong>Background: </strong>Lapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs in dogs remain unknown.</p><p><strong>Objective: </strong>To evaluate the DAEs in dogs with UC treated with lapatinib and piroxicam.</p><p><strong>Animals: </strong>Eighty-five dogs with UC were treated with lapatinib/piroxicam and 42 were treated with piroxicam alone.</p><p><strong>Materials and methods: </strong>This retrospective cohort study evaluated dogs diagnosed with UC and treated with lapatinib and piroxicam, and those treated with piroxicam alone. Relevant data were extracted from the medical records. The DAEs were assessed using the Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Events and Naranjo algorithm. The log-rank test and Cox proportional hazards model were used to assess progression-free survival (PFS).</p><p><strong>Results: </strong>DAEs occurred in 31.8% of the dogs in the lapatinib/piroxicam group, with alopecia and hyperpigmentation being the most common. In the piroxicam group, DAEs were observed in 7.1% of dogs. The relative risk of developing DAEs in the lapatinib/piroxicam group was 4.4 (p < 0.01). In the lapatinib/piroxicam group, DAEs were associated with a longer PFS (p < 0.03). The Cox proportional hazards model identified DAEs as independent prognostic factors for improved PFS (hazard ratio, 0.52, p < 0.05).</p><p><strong>Conclusions and clinical relevance: </strong>Lapatinib treatment in dogs induces DAEs, which serve as biomarkers of lapatinib efficacy in canine UC.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"752-760"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147487433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osseous Changes in Young Cats With Inflammatory Aural Polyps: A Cone Beam Computed Tomography Analysis.","authors":"Adriana Colón Rodríguez, Denae N Campanale, David Sarment, Michael S Canfield","doi":"10.1111/vde.70100","DOIUrl":"10.1111/vde.70100","url":null,"abstract":"<p><strong>Background: </strong>Computed tomography is an imaging tool that has been used in veterinary medicine with excellent results to evaluate changes associated with inflammatory aural polyps (IPs) in feline patients. There is no known veterinary literature investigating the use of cone beam computed tomography (CBCT) to identify osseous changes in the middle and inner ear associated with IPs in cats.</p><p><strong>Hypothesis/objectives: </strong>This study evaluates the utility of CBCT to identify osseous changes in the middle and inner ear associated with IPs in young cats, and to determine the frequency of osseous changes in young cats.</p><p><strong>Animals: </strong>Review of 38 medical records of cats diagnosed with IPs presented to a private practice dermatological service.</p><p><strong>Materials and methods: </strong>CBCT bone window studies at a 0.3-mm isotropic slice thickness were performed without contrast and later evaluated by a board-certified veterinary radiologist.</p><p><strong>Results: </strong>CBCT images were adequate to identify normal and affected structures in the middle and inner ear of cats. The most common osseous changes in descending order of occurrence were mild-to-severe bulla thickening (65.7%), auditory tube widening (52.6%), and cochlear and ossicular chain lysis (7.8%).</p><p><strong>Conclusions and clinical relevance: </strong>This study demonstrates that CBCT is useful as an initial imaging diagnostic when an IP is suspected in cats. Osseous changes such as tympanic bulla thickening, cochlear and ossicular chain lysis, and auditory tube and internal acoustic meatus widening on CBCT imaging could be indicatory of an inflammatory aural polyp.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"833-840"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Outcomes and Owner Assessment in Canine Sebaceous Adenitis Across Breeds: A Multicentre Retrospective Analysis and Owner Survey.","authors":"Haley Batt, Joya Griffin, Michael W Daniels, Julia Miller","doi":"10.1111/vde.70095","DOIUrl":"10.1111/vde.70095","url":null,"abstract":"<p><strong>Background: </strong>Sebaceous adenitis (SA) is an idiopathic dermatological condition with numerous treatment modalities and variable clinical outcomes. No studies have compared breed response to therapies or evaluated owner perception of the disease.</p><p><strong>Objectives: </strong>Goals of this retrospective analysis were to evaluate response to therapy in dogs with SA, identify if breed or treatment modality impacted therapeutic outcome and assess owner perception of response to implemented therapies.</p><p><strong>Materials and methods: </strong>Medical records over a 10-year period from a multicentre veterinary dermatology group were evaluated and an owner survey was conducted. Response to therapy was based on percentage reduction in medication scores at the start of treatment compared to maintenance and the number of flares after attaining maintenance. Time to maintenance was calculated for each treatment modality category. Owner survey responses were compared to objective clinical response categories.</p><p><strong>Results: </strong>One hundred and twenty-two dogs with SA were included; 35 respondents completed the survey. The number of cases in objective clinical response categories were as follows: excellent in 23 cases (18.9%), good in 36 (29.5%), fair in 26 (21.3%), no improvement in 13 (10.7%) and progressive in 23 (18.9%). Medication score differences by breed were not statistically significant (p-value 0.114). Dogs treated with multimodal therapy achieved maintenance the fastest. Thirty-nine percent of dogs experienced a flare after reaching maintenance. Owner perceptions did not align significantly with objective response categories.</p><p><strong>Conclusions and clinical relevance: </strong>In SA, therapeutic outcomes cannot be predicted based on breed or treatment modality, confirming the need for tailored case management and medication adjustments based on individual treatment response.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"650-658"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Oral Baicalin in Canine Atopic Dermatitis: A Randomised Placebo Controlled Trial.","authors":"Xiao-Liang Qian, Jiang Lu, Wei Lu, Wei-Xiang Xu, Zhong-Hua Jiang","doi":"10.1111/vde.70089","DOIUrl":"10.1111/vde.70089","url":null,"abstract":"<p><strong>Background: </strong>Baicalin has shown efficacy in various dermatitis models in animals. However, its therapeutic effects on naturally occurring canine atopic dermatitis (cAD) have not been evaluated.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of baicalin in dogs with cAD.</p><p><strong>Animals: </strong>56 client-owned dogs were enrolled.</p><p><strong>Materials and methods: </strong>All dogs were randomly divided to receive oral baicalin or placebo over a 90day period. All subjects had veterinary evaluations using the Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04) during the trial and owners were requested to evaluate itching using the pruritus Visual Analog Scale (PVAS) and to complete a quality-of-life (QoL) questionnaire at Day (D)0 and D90. Additionally, the transepidermal water loss (TEWL), total serum IgE levels (IgE), complete blood count and serum biochemical results were measured at D0 and D90.</p><p><strong>Results: </strong>The significant decreases in CADESI-04 (p < 0.001), PVAS (p < 0.001), TEWL (p = 0.014), IgE (p < 0.001) and QoL scores (p < 0.001) were observed in the baicalin group D90 compared to baseline. When compared to placebo, the baicalin group had significantly lower scores in CADESI-4 and PVAS (p < 0.001). A significantly higher proportion of subjects in the baicalin group showed a good-to-excellent treatment response (82.1%) compared to those in the placebo group (35.7%). The treatment was well tolerated.</p><p><strong>Conclusions and relevance: </strong>Baicalin had a significant benefit in alleviating pruritus and reducing clinical signs in dogs with mild-to-moderate cAD and was well tolerated.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"592-600"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148044106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy and Safety of Adjunctive 0.015% Triamcinolone Acetonide Topical Spray With Lokivetmab Versus Lokivetmab Monotherapy as 'Reactive Therapy' for Canine Atopic Dermatitis: A Randomised, Single-Blinded, Controlled Preliminary Trial.","authors":"Frane Banovic, Michaela Austel, Lauren Johnson, Cristiano von Simson","doi":"10.1111/vde.70102","DOIUrl":"10.1111/vde.70102","url":null,"abstract":"<p><strong>Background: </strong>Lokivetmab is considered an effective systemic therapy for dogs with atopic dermatitis (AD); however, utilisation of lokivetmab with adjunctive topical anti-inflammatory glucocorticoids has not been investigated in canine AD.</p><p><strong>Objectives: </strong>To evaluate the efficacy and safety of the combination therapy of lokivetmab and 0.015% triamcinolone acetonide (TCA) spray in dogs with AD.</p><p><strong>Animals: </strong>Twenty dogs with nonseasonal AD.</p><p><strong>Materials and methods: </strong>This study was a randomised, single-blinded (investigators only) 4-week controlled trial. Dogs were randomised to receive lokivetmab monotherapy or lokivetmab-TCA spray per manufacturer instructions. Clinical assessments included the Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04), CADESI-04E (i.e., extracted erythema grade alone) and the 10-grade pruritus Visual Analog Scale (PVAS10) at Day (D)0, D14 and D28. Complete blood count and serum biochemical analysis were performed on D0 and D28.</p><p><strong>Results: </strong>The median CADESI-04 and CADESI-04E scores in the lokivetmab-TCA group were significantly reduced on D14 (p < 0.05 for both) and D28 (p < 0.01 for both) compared to baseline; there were no significant differences in lesional scores at any time point for the lokivetmab monotherapy group. Lokivetmab-TCA significantly reduced CADESI-04E values compared to the lokivetmab monotherapy group on D28 (p = 0.04). Both interventions significantly reduced PVAS10 scores on D14 and D28 compared to D0 (p < 0.05 for both groups).</p><p><strong>Conclusions and clinical relevance: </strong>Topical application of TCA spray may be a useful and safe adjunctive therapy for systemic lokivetmab to alleviate pruritus and clinical lesions in the initial management of canine AD patients.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"601-608"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148333014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, Histopathological and Epidemiological Features of Dorsal Melanotrichia of Poodles and Poodle Crosses.","authors":"Jiwon Kim, Keith Linder, Wayne Rosenkrantz, M Kelly Keating, Carine Laporte, Rebecca Mount, Anthea Schick","doi":"10.1111/vde.70066","DOIUrl":"10.1111/vde.70066","url":null,"abstract":"<p><strong>Background: </strong>Poodles and poodle cross-breds develop a poorly described dorsal truncal hair coat condition informally called \"doodle dysplasia\".</p><p><strong>Hypothesis/objective: </strong>To characterise the clinical, histopathological and epidemiological features of dorsal melanotrichia in poodles and poodle crosses.</p><p><strong>Animals: </strong>Twenty-nine privately-owned poodles and poodle cross-breds with an unidentified cause for dorsal melanotrichia in the United States.</p><p><strong>Materials and methods: </strong>Retrospective and prospective case recruitment from private/academic dermatology and general practices, and involved record review, owner questionnaire, and dermatohistopathological analysis between 2019 and 2024. Inclusion criteria were poodles and poodle cross-breds with coat colour changes restricted to the dorsum, with or without other concurrent dermatological lesions or systemic signs.</p><p><strong>Results: </strong>The average age of onset was 4 years. Summer was the most commonly reported season of onset (46% dogs), and recent grooming was noted in 57% of dogs with the information available. The most common pattern and distribution were serpiginous in 67% of dogs, and dorsal thorax and lumbar in 39% of dogs. Additional changes were alopecia and alteration of texture. Of those dogs with resolution, 71% had recurrence of coat colour and texture alterations 12 months or 24 months later. Histopathological changes were overall mild, with the most common being outer root sheath apoptosis and altered pigmentation in follicles, without strong evidence to support a dysplasia.</p><p><strong>Conclusion and clinical relevance: </strong>\"Doodle dysplasia\" is a condition with a possible seasonal and/or environmental component. Given the lack of clear evidence for dysplasia, we propose a new name: dorsal melanotrichia of poodles and poodle crosses.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"761-774"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147481085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of 0.5% Tretinoin in the Treatment of Equine Aural Plaques.","authors":"Felipe Sperandio de Mattos, Lissandro Gonçalves Conceição, Ytalo Galinari Henrique Schuartz, Vitória Régia Melo Silva, Cintia Fernandes Fidélis, Fernanda Campos Mansur, Cristian Silva Teixeira, Yame Fabres Robaina Sancler-Silva, Jose Paes Oliveira-Filho, Alexandre Secorun Borges, Cristiana Raach Bromberger, José Dantas Ribeiro Filho, Marcel Ferreira Bastos Avanza, José Ricardo Barboza Silva, Raffaella Bertoni Cavalcanti Teixeira","doi":"10.1111/vde.70090","DOIUrl":"10.1111/vde.70090","url":null,"abstract":"<p><strong>Background: </strong>Equine aural plaques are a benign form of auricular papillomatosis caused by equine papillomavirus. Despite the efficacy of 5% imiquimod cream, a marked local reaction is frequently observed during therapy, often requiring sedation before application.</p><p><strong>Hypothesis/objectives: </strong>The aim of this study was to evaluate the efficacy and potential adverse effects of 0.5% topical tretinoin in the treatment of equine aural plaques. We hypothesised that tretinoin would be effective, with fewer adverse effects compared to imiquimod.</p><p><strong>Animals: </strong>The study included 10 horses of both sexes, aged between 7 months and 15 years, diagnosed with unilateral or bilateral aural plaques (totalling 17 ears).</p><p><strong>Materials and methods: </strong>This was a controlled clinical trial. Three horses underwent a pilot study, in which only one ear per animal was treated to allow for intra-animal comparison, while the remaining seven horses received treatment in both ears. Lesions were classified into three groups based on the percentage of the inner auricular surface affected. Treatment was performed with 0.5% topical tretinoin once daily until lesion stabilisation or resolution. Lesion characteristics, treatment response, adverse effects and recurrence were evaluated.</p><p><strong>Results: </strong>Sixty-five percent of the ears exhibited an improvement of > 50% following treatment. On average, maximal lesion resolution occurred within 52.8 days (range 6-74 days). None of the horses exhibited severe sensitivity during the treatment period, allowing for ear manipulation throughout the study.</p><p><strong>Conclusions and clinical relevance: </strong>The topical application of 0.5% tretinoin cream proved to be an effective and safe treatment for equine aural plaques. Further studies with a larger sample size and long-term follow-up are recommended to optimise treatment protocols.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"664-671"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148057217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oclacitinib for Controlling Pruritus and Associated Skin Lesions in 16 Horses With Allergic Dermatitis.","authors":"Maturawan Tunhikorn, Photchanun Maneephan, Natcha Tovanakasame, Chalidaporn Kampang, Pusprapa Jandee, Panpanga Sangsuriya, Nuttawut Nuchprayoon","doi":"10.1111/vde.70091","DOIUrl":"10.1111/vde.70091","url":null,"abstract":"<p><strong>Background: </strong>Oclacitinib is a Janus kinase inhibitor approved for the treatment of pruritus associated with allergic dermatitis in dogs and may be effective in horses.</p><p><strong>Objectives: </strong>To evaluate the efficacy of oclacitinib in reducing pruritus and skin lesions in horses with allergic dermatitis.</p><p><strong>Animals: </strong>Sixteen horses aged ≥ 18 months.</p><p><strong>Materials and methods: </strong>Horses received oclacitinib at 0.25 mg/kg orally once daily for 21 days. Changes in haematological and biochemical parameters were measured on Day (D)0 and D21. The owners were instructed to evaluate the horses using the pruritus Visual Analog Scale (PVAS) on D0, D4, D7, D10, D14, D17 and D21. A veterinary surgeon evaluated skin lesions using a veterinarian lesion score (VLS) and veterinarian alopecia score (VAS) on D0, D7, D14 and D21.</p><p><strong>Results: </strong>From baseline to D21, the median (range) PVAS changed from 5 (4-8) to 2.5 (2-4.5), VLS from 19 (2-42) to 10 (1-38) and VAS from 2 (2, 3) to 2 (1, 2). Of all 16 horses, improvements in PVAS, VLS and VAS were observed in 15, 12 and 8 horses, respectively. Blood profiles revealed significantly increased aspartate aminotransferase, gamma-glutamyl transferase and creatinine levels. White blood cell count, lymphocyte count and blood urea nitrogen significantly decreased. Creatine kinase levels showed individual variability.</p><p><strong>Conclusions and clinical relevance: </strong>Oclacitinib effectively reduced pruritus and improved skin lesions in horses with allergic dermatitis. However, caution is advised when administering the drug to horses with renal, hepatic or muscular disorders.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"672-680"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148139126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crescentic Hair Shaft Defects and Piedra-Like Lesions With Follicular Invasion in Northern Elephant Seals (Mirounga angustirostris).","authors":"Niki Nabavi-Mosavi, Christopher P Champion, Vivian M Lee, Mahdi Ayoubi, Pamela K Yochem, Brent S Stewart, Shotaro Nakagun, Margaret E Martinez, Aline Rodrigues-Hoffmann, Pádraig J Duignan, Jeanine Peters-Kennedy","doi":"10.1111/vde.70088","DOIUrl":"10.1111/vde.70088","url":null,"abstract":"<p><strong>Background: </strong>Historically, dermatological disease is a common cause for rescue of northern elephant seals (NES) in California, yet its aetiology and pathogenesis remain poorly understood.</p><p><strong>Objectives: </strong>To provide the first formal histological and ultrastructural description of two hair shaft lesions in NES: crescentic hair shaft defects (CHSD) and fungal (piedra)-like lesions (PLL).</p><p><strong>Animals: </strong>Forty-one animals from The Marine Mammal Center and 10 animals from San Nicolas Island were examined, 38 with skin lesions and 13 without.</p><p><strong>Materials and methods: </strong>Age, sex, comorbidities, cause-of-death, gross skin lesions and evidence of northern elephant seal skin disease (NESSD) were recorded. Histologically, we examined each case for CHSD, PLL, suppurative luminal folliculitis (SLF), furunculosis, bacteria and fungal elements within CHSD, and fungal elements within follicular lesions. Grocott-Gomori methenamine silver, Gram and Fontana-Masson's stains were performed on 17, 11 and 8 cases, respectively.</p><p><strong>Results: </strong>NESSD, CHSD, PLL, SLF and furunculosis were noted in 10 of 38 (26%), 23 of 38 (61%), 23 of 38 (61%), 20 of 38 (53%) and 6 of 38 (16%) animals with skin lesions, respectively. Within CHSD lesions, bacteria were identified in 13 animals and fungi in seven. CHSD and PLL frequently co-occurred, limited to NES over 7.5 months old and often associated with SLF, and were observed exclusively in animals with dermatological disease and present in most cases of NESSD, suggesting a pathological association. Panfungal PCR from 10 animals identified several fungi, including Cladosporium spp., a reported cause of white piedra in humans.</p><p><strong>Conclusions and clinical relevance: </strong>Although the aetiology of CHSD remains unclear, we suggest that fungal and/or bacterial colonisation of the hair shaft may contribute.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"876-887"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148303308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}